Skip to main content

Table 1 PRLR Expression and ABBV-176 Cytotoxicity in Human Tumor Cell Lines

From: ABBV-176, a PRLR antibody drug conjugate with a potent DNA-damaging PBD cytotoxin and enhanced activity with PARP inhibition

  PRLR Expressiona ABBV-176 IC50 (nM)b h16f-MMAE IC50 (nM) b
Breast cancer
 T47D 26,000 0.0055 (0.006) 0.22
 CAMA1 10,000 0.01 5.2
 BT-474 10,000 0.24 (0.04) 0.56
 MCF7 8000 0.32 (0.3) > 22
 MDA-MB-361 5–10,000 0.77 (0.2) 0.96
 SKBR3 5–10,000 0.26 3.67
 UACC812 ~ 3500 >  22 > 22
 MDA-MB-231 Below detection >  22 > 22
Prostate
 22RV1 8000 0.01 > 22
Endometrial
 AN3CA 8300 0.6 22
Ovarian
 SMOV2 ~ 2300 0.16 > 22
Colorectal
 SW403 11,000 0.11 17
Liver
 HepG2 n.d. 8.6 > 22
 HuH-7 ~ 14,000 5.2 > 22
  1. IC50 half maximal inhibitory concentration, PRLR prolactin receptor, n.d. not done due to cell aggregation
  2. aCell surface PRLR per cell is indicated based on quantitative FACS
  3. bCell viability was determined following incubation with indicated ADC for 144 h. The values represent IC50s. Averages are shown when multiple experiments were performed, with standard deviations in parentheses. Unconjugated anti-PRLR antibody does not inhibit growth of any of these cell lines